Table 1.
Current Advances in ZIKV Vaccine Development [152]
| Platform | Candidate Vaccine | Immunogen | Adjuvant Type | Registry ID | Sponsor Name | Phase | Study start date | Completion Date anticipated | Age | Sample size | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA-based | GLS-5700 | prME | None | NCT02809443 | GeneOne Life Science/Inovio Pharmaceuticals | 1 | 7/1/16 | 12/1/17 | Adult | 40 | [96] |
| GLS-5700 | prME | None | NCT02887482 | GeneOne Life Science/Inovio Pharmaceuticals | 1 | 8/1/16 | 6/1/18 | Adult | 160 | [96,153] | |
| VRC-ZKADNA085-00-VP | prME | None | NCT02840487 | NIAID | 1 | 8/2/16 | 12/28/19 | Adult | 80 | [95] | |
| VRC-ZKADNA090-00-VP | prME | None | NCT02996461 | NIAID | 1 | 12/16/16 | 12/28/19 | Adult | 45 | [95] | |
| VRC-ZKADNA090-00-VP | prME | None | NCT03110770 | NIAID | 2 | 3/29/17 | 1/1/20 | Child/Adult | 2338 | [94,95] | |
| IWTO* | ZIKV PIV | whole virus | Aluminum salts | NCT02963909 | NIAID | 1 | 11/1/16 | 10/30/18 | Adult | 75 | [89] |
| ZIKV PIV | whole virus | Aluminum salts | NCT02952833 | NIAID | 1 | 10/14/16 | 12/5/18 | Adult | 91 | [89] | |
| ZIKV PIV | whole virus | Aluminum salts | NCT02937233 | BIDMC | 1 | 12/8/16 | 6/4/18 | Adult | 36 | [89] | |
| ZIKV PIV | whole virus | Aluminum salts | NCT03008122 | NIAID | 1 | 2/24/17 | 1/15/20 | Adult | 90 | [87,89] | |
| PIZV or TAK-426 | whole virus | Aluminum salts | NCT03343626 | Takeda | 1 | 11/13/17 | 2/28/21 | Adult | 240 | [87,89] | |
| VLA1601 | whole virus | Aluminum salts | NCT03425149 | Valneva Austria GmbH | 1 | 2/24/18 | 11/16/18 | Adult | 67 | [87,89] | |
| BBV121 | whole virus | Aluminum salts | CTRI/2017/05/008539 | Bharat Biotech | 1 | 6/1/17 | Not listed | Adult | 48 | [90] | |
| Recombinant viral vector | rZIKV/D4Δ30-713 | prME in DENV backbone | None | NCT03611946 | NIAID | 1 | 7/6/18 | 9/30/19 | Adult | 28 | - |
| MV-Zika | prME | None | NCT02996890 | Themis Bioscience | 1 | 4/4/17 | 4/17/18 | Adult | 48 | [154] | |
| Peptide | AGS-v | Mosquito salivary proteins | Not specified | NCT03055000 | NIH | 1 | 2/15/17 | 12/28/18 | Adult | 49 | - |
| mRNA | mRNA-1325 | prME | None | NCT03014089 | Moderna Therapeutics | 2 | 12/1/16 | 2/1/19 | Adult | 90 | [103,155] |
IWOT* Inactivated whole target organism